Axsome Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Axsome Therapeutics, Inc. (AXSM) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-287.22-239.24-187.13-130.40-102.90-68.35-30.97
Depreciation & Amortization7.966.834.402.230.860.690.05
Stock Based Compensation85.2262.6237.7320.8014.760.000.00
Change in Working Capital33.90-28.3923.670.230.1514.331.52
Change in Accounts Receivable-47.18-57.12-37.700.000.000.000.00
Change in Inventory-2.44-8.16-1.33-0.010.000.000.00
Change in Accounts Payable31.322.0725.46-0.362.560.000.00
Change in Other Working Capital31.7334.8137.240.68-2.150.000.00
Other Operating Activities31.7350.523.3419.7222.196.950.38
Net Cash from Operating Activities-128.41-145.08-116.51-108.23-78.46-46.38-30.05
Investing Activities
Capital Expenditures-0.27-0.58-0.700.310.050.02-0.03
Acquisitions0.000.00-53.000.000.000.000.00
Net Cash from Investing Activities-0.27-0.58-53.70-0.31-0.05-0.02-0.03
Financing Activities
Debt Repayment-0.99-1.44-0.49-0.31-21.66-7.24-3.33
Common Stock Issued40.78271.17250.017.2114.13238.2312.88
Common Stock Repurchased0.00-1.84-0.53-0.180.000.000.00
Other Financing Activities-12.63-23.32-9.90-0.18-1.100.00-0.03
Net Cash from Financing Activities57.84331.01284.5811.1342.41252.3910.03
Summary
Net Change in Cash-70.84185.35114.37-97.40-36.09206.00-20.05
Cash at Beginning of Period386.19200.8486.47183.88219.9713.9734.02
Cash at End of Period315.35185.35200.8486.47183.88219.9713.97
Free Cash Flow-128.68-145.66-117.21-108.53-78.50-46.39-30.09
Supplemental Disclosures
Interest Paid19.6916.737.694.632.101.290.77